(TWST) Twist Bioscience - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US90184D1000
Stock: Synthetic Genes, Oligo Pools, NGS Tools, Antibody Libraries, Viral Controls
Total Rating 30
Risk 37
Buy Signal 0.55
| Risk 5d forecast | |
|---|---|
| Volatility | 67.5% |
| Relative Tail Risk | -6.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.34 |
| Alpha | -13.19 |
| Character TTM | |
|---|---|
| Beta | 1.696 |
| Beta Downside | 1.165 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.97% |
| CAGR/Max DD | 0.51 |
EPS (Earnings per Share)
Revenue
Description: TWST Twist Bioscience January 15, 2026
Twist Bioscience (NASDAQ:TWST) is a U.S.-based synthetic DNA manufacturer that produces custom gene fragments, oligo pools, and related reagents for a broad range of applications, including therapeutics, diagnostics, agricultural biotech, and emerging fields such as DNA data storage and computing.
Its product suite spans synthetic genes for drug discovery, next-generation sequencing (NGS) library kits (exome, custom panels, methylation detection), and specialty controls for viral diagnostics (e.g., SARS-CoV-2, monkeypox). The company also offers antibody-engineering solutions and a strategic partnership with bitBiome to expand its microbial-genomics capabilities.
Key quantitative signals (as of FY 2023) include revenue of roughly $400 million, a gross margin near 70 %, and a cash balance exceeding $300 million, which together provide runway for R&D and capacity expansion. The synthetic DNA market is projected to grow at a CAGR of 12-15 % through 2030, driven by accelerating demand for CRISPR-based therapies and large-scale NGS diagnostics-both of which are core end-markets for Twist.
For a deeper quantitative assessment, consult the ValueRay platform’s detailed TWST valuation model.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -76.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -2.35 > 1.0 |
| NWC/Revenue: 57.06% < 20% (prev 83.49%; Δ -26.42% < -1%) |
| CFO/TA -0.08 > 3% & CFO -51.0m > Net Income -76.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.1m) vs 12m ago 3.24% < -2% |
| Gross Margin: 51.62% > 18% (prev 0.45%; Δ 5118 % > 0.5%) |
| Asset Turnover: 62.82% > 50% (prev 54.26%; Δ 8.56% > 0%) |
| Interest Coverage Ratio: -528.4 > 6 (EBITDA TTM -51.2m / Interest Expense TTM 143.0k) |
Altman Z'' -13.21
| A: 0.35 (Total Current Assets 303.9m - Total Current Liabilities 80.4m) / Total Assets 638.1m |
| B: -2.12 (Retained Earnings -1.35b / Total Assets 638.1m) |
| C: -0.12 (EBIT TTM -75.6m / Avg Total Assets 623.3m) |
| D: -7.42 (Book Value of Equity -1.35b / Total Liabilities 182.0m) |
| Altman-Z'' Score: -13.21 = D |
Beneish M -2.75
| DSRI: 1.07 (Receivables 50.1m/39.3m, Revenue 391.6m/330.2m) |
| GMI: 0.86 (GM 51.62% / 44.59%) |
| AQI: 1.41 (AQ_t 0.25 / AQ_t-1 0.17) |
| SGI: 1.19 (Revenue 391.6m / 330.2m) |
| TATA: -0.04 (NI -76.6m - CFO -51.0m) / TA 638.1m) |
| Beneish M-Score: -2.75 (Cap -4..+1) = A |
What is the price of TWST shares?
As of February 15, 2026, the stock is trading at USD 49.11 with a total of 1,063,800 shares traded.
Over the past week, the price has changed by -0.26%, over one month by +22.10%, over three months by +64.25% and over the past year by +4.78%.
Over the past week, the price has changed by -0.26%, over one month by +22.10%, over three months by +64.25% and over the past year by +4.78%.
Is TWST a buy, sell or hold?
Twist Bioscience has received a consensus analysts rating of 4.17.
Therefore, it is recommended to buy TWST.
- StrongBuy: 6
- Buy: 3
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the TWST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.9 | 1.6% |
| Analysts Target Price | 49.9 | 1.6% |
| ValueRay Target Price | 50.2 | 2.2% |
TWST Fundamental Data Overview February 12, 2026
P/S = 7.7728
P/B = 6.673
Revenue TTM = 391.6m USD
EBIT TTM = -75.6m USD
EBITDA TTM = -51.2m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 183.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.03b USD (3.04b + Debt 183.9m - CCE 197.9m)
Interest Coverage Ratio = -528.4 (Ebit TTM -75.6m / Interest Expense TTM 143.0k)
EV/FCF = -34.93x (Enterprise Value 3.03b / FCF TTM -86.7m)
FCF Yield = -2.86% (FCF TTM -86.7m / Enterprise Value 3.03b)
FCF Margin = -22.15% (FCF TTM -86.7m / Revenue TTM 391.6m)
Net Margin = -19.56% (Net Income TTM -76.6m / Revenue TTM 391.6m)
Gross Margin = 51.62% ((Revenue TTM 391.6m - Cost of Revenue TTM 189.4m) / Revenue TTM)
Gross Margin QoQ = 52.05% (prev 51.35%)
Tobins Q-Ratio = 4.75 (Enterprise Value 3.03b / Total Assets 638.1m)
Interest Expense / Debt = 0.08% (Interest Expense 143.0k / Debt 183.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -59.7m (EBIT -75.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.78 (Total Current Assets 303.9m / Total Current Liabilities 80.4m)
Debt / Equity = 0.40 (Debt 183.9m / totalStockholderEquity, last quarter 456.1m)
Debt / EBITDA = -0.69 (negative EBITDA) (Net Debt 35.3m / EBITDA -51.2m)
Debt / FCF = -0.41 (negative FCF - burning cash) (Net Debt 35.3m / FCF TTM -86.7m)
Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.29% (Net Income -76.6m / Total Assets 638.1m)
RoE = -16.58% (Net Income TTM -76.6m / Total Stockholder Equity 461.8m)
RoCE = -13.50% (EBIT -75.6m / Capital Employed (Equity 461.8m + L.T.Debt 98.0m))
RoIC = -12.93% (negative operating profit) (NOPAT -59.7m / Invested Capital 461.8m)
WACC = 11.48% (E(3.04b)/V(3.23b) * Re(12.17%) + D(183.9m)/V(3.23b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 12.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.07%
Fair Price DCF = unknown (Cash Flow -86.7m)
EPS Correlation: 69.23 | EPS CAGR: 27.85% | SUE: -0.26 | # QB: 0
Revenue Correlation: 98.93 | Revenue CAGR: 22.72% | SUE: 1.04 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.53 | Chg30d=-0.060 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-1.97 | Chg30d=+0.145 | Revisions Net=+0 | Growth EPS=+6.9% | Growth Revenue=+16.6%
EPS next Year (2027-09-30): EPS=-1.89 | Chg30d=+0.165 | Revisions Net=+0 | Growth EPS=+4.3% | Growth Revenue=+15.0%
P/B = 6.673
Revenue TTM = 391.6m USD
EBIT TTM = -75.6m USD
EBITDA TTM = -51.2m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 183.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.03b USD (3.04b + Debt 183.9m - CCE 197.9m)
Interest Coverage Ratio = -528.4 (Ebit TTM -75.6m / Interest Expense TTM 143.0k)
EV/FCF = -34.93x (Enterprise Value 3.03b / FCF TTM -86.7m)
FCF Yield = -2.86% (FCF TTM -86.7m / Enterprise Value 3.03b)
FCF Margin = -22.15% (FCF TTM -86.7m / Revenue TTM 391.6m)
Net Margin = -19.56% (Net Income TTM -76.6m / Revenue TTM 391.6m)
Gross Margin = 51.62% ((Revenue TTM 391.6m - Cost of Revenue TTM 189.4m) / Revenue TTM)
Gross Margin QoQ = 52.05% (prev 51.35%)
Tobins Q-Ratio = 4.75 (Enterprise Value 3.03b / Total Assets 638.1m)
Interest Expense / Debt = 0.08% (Interest Expense 143.0k / Debt 183.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -59.7m (EBIT -75.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.78 (Total Current Assets 303.9m / Total Current Liabilities 80.4m)
Debt / Equity = 0.40 (Debt 183.9m / totalStockholderEquity, last quarter 456.1m)
Debt / EBITDA = -0.69 (negative EBITDA) (Net Debt 35.3m / EBITDA -51.2m)
Debt / FCF = -0.41 (negative FCF - burning cash) (Net Debt 35.3m / FCF TTM -86.7m)
Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.29% (Net Income -76.6m / Total Assets 638.1m)
RoE = -16.58% (Net Income TTM -76.6m / Total Stockholder Equity 461.8m)
RoCE = -13.50% (EBIT -75.6m / Capital Employed (Equity 461.8m + L.T.Debt 98.0m))
RoIC = -12.93% (negative operating profit) (NOPAT -59.7m / Invested Capital 461.8m)
WACC = 11.48% (E(3.04b)/V(3.23b) * Re(12.17%) + D(183.9m)/V(3.23b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 12.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.07%
Fair Price DCF = unknown (Cash Flow -86.7m)
EPS Correlation: 69.23 | EPS CAGR: 27.85% | SUE: -0.26 | # QB: 0
Revenue Correlation: 98.93 | Revenue CAGR: 22.72% | SUE: 1.04 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.53 | Chg30d=-0.060 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-1.97 | Chg30d=+0.145 | Revisions Net=+0 | Growth EPS=+6.9% | Growth Revenue=+16.6%
EPS next Year (2027-09-30): EPS=-1.89 | Chg30d=+0.165 | Revisions Net=+0 | Growth EPS=+4.3% | Growth Revenue=+15.0%